AustCancer subsidiary signs distribution deal
06 July, 2004 by Renate KrelleACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.
Aldara gets green light for actinic keratosis
06 July, 2004 by Staff WritersUS regulators have given the green light for doctors to prescribe Minnesota-based 3M's Aldara for precancerous skin lesions called actinic keratosis. 3M is also awaiting approval for Aldara's use against a common form of non-melanoma skin cancer, superficial basal cell carcinoma.
New epilepsy patent for Bionomics
05 July, 2004 by Renate KrelleAdelaide epilepsy specialist Bionomics (ASX:BNO) has announced that its patent covering a link between the nicotinic acetylcholine receptor ion channel subunit and epilepsy has been accepted in New Zealand.
Life Therapeutics signs MOU with UK's BioProducts
30 June, 2004 by Melissa TrudingerLife Therapeutics, the company formerly known as Gradipore (ASX: GDP), has signed a memorandum of understanding with UK company Bio Products Laboratories (BPL) over the potential acquisition of a recombinant human anti-D immunoglobulin (rAnti-D).
Take two: Peplin's revised IND filed
29 June, 2004 by Melissa TrudingerBrisbane-based Peplin Biotech (ASX: PEP) announced today that its US partner Allergan had filed two amended IND applications with the FDA for Peplin's PEP005, a topical formulation for skin cancer treatment.
Horse hormones put athletes at risk
24 June, 2004 by Graeme O'NeillA Sydney endocrinologist says athletes who inject themselves with the illegal drug Equigen put their lives and careers at risk for no benefit.
AustCancer boosted by takeover target's good news
22 June, 2004 by Graeme O'NeillAlabama-based Galenica Pharmaceuticals has delighted its prospective new owner, Sydney oncology specialist Australian Cancer Technology(ASX:ACU), by announcing an agreement with New York's Memorial Sloan-Kettering Cancer Centre to evaluate Galenica's promising immunity enhancer GPI-0100 in several Phase II clinical trials.
For cancer research, charity begins on Ebay
21 June, 2004 by Staff WritersProstate Cancer Foundation chief executive Leslie Michelson is turning to eBay to raise research dollars as baby boomers approach the danger age when the disease -- the second-leading cause of cancer deaths in US males -- is most likely to strike.
Shareholders back AGT-ChemGenex merger
21 June, 2004 by Iain ScottShareholders of Melbourne-based AGT Biosciences (ASX:AGT) have backed the company's merger with privately-held Californian firm ChemGenex Therapeutics.
News: Researcher's diabetes quest earns reward for excellence
21 June, 2004 by Melissa TrudingerProf Len Harrison, of the Walter and Eliza Hall Institute, has been awarded the David Rumbough award for scientific excellence by the Juvenile Diabetes Research Foundation International for his research towards finding a cure for type 1 diabetes.
Life Therapeutics aims for profit by 2006
18 June, 2004 by Renate KrelleLife Therapeutics -- formerly known as Gradipore (ASX:GDP) -- today capped off its 200-day turnaround plan with a set of profit projections that culminated in a forecast overall profit for the company in 2006 of AUD$4.5 million.
Garvan to team with Shanghai researchers on diabetes project
17 June, 2004 by Graeme O'NeillBy 2025, as many as 157 million overweight Chinese are likely to be suffering from non-insulin dependent (Type 2) diabetes, more than the total for the entire world today.
Lacklustre debut for Regenera
16 June, 2004 by Renate KrellePerth-based opthamology specialist Regenera (ASX:RGA) experienced a lacklustre debut on ASX today. After opening at $0.47 and trading as high as $0.50, it fell below its issue price and at time of writing was trading at $0.49.
Singapore cancer patients implanted with Psivida's Biosilicon
15 June, 2004 by Graeme O'NeillTwo patients in Singapore General Hospital suffering from inoperable liver tumours have become the first cancer patients in the world to be treated with an experimental in situ radiation therapy developed by Perth nano-biotech company Psivida (ASX:PSD).
CSIRO develops new cancer classifier
15 June, 2004 by Melissa TrudingerCSIRO statisticians have developed a new molecular classifier tool which is being tested on clinical bone marrow samples from children with acute lymphoblastic leukaemia (ALL) -- the most common cancer in children under 12 -- as a potential diagnostic tool for identifying the disease and its subtypes.
